Ipragliflozin ameliorates liver damage in non-alcoholic fatty liver disease
Teruki Miyake(Ehime University), Yoichi Hiasa(Ehime University Hospital), Tetsuju Niiya(Matsuyama Shimin Hospital), Masashi Hirooka(Ehime University), Shinya Furukawa(Ehime University Hospital), Hiroaki Miyaoka(Saiseikai Matsuyama Hospital), Masanori Abe(Ehime University), Fujimasa Tada(Ehime Prefectural Central Hospital), Bunzo Matsuura(Ehime University), Yohei Koizumi(Ehime University), Osamu Yoshida(Ehime University Hospital), Shin Yamamoto(Massachusetts General Hospital), Takenori Sakai(Yawata Medical Center), Teru Kumagi(Ehime University), Sakiko Yoshida(Matsuyama Shimin Hospital), Hidenori Senba(Ehime University)
Cited by 48
Related Papers
Constitutive activation of the 41-/43-kDa mitogen-activated protein kinase signaling pathway in human tumors
|Oncogene|1999|693
Evidence-based clinical practice guidelines for Liver Cirrhosis 2020
|Journal of Gastroenterology|2021|424
A Glycine-rich RNA-binding Protein Mediating Cold-inducible Suppression of Mammalian Cell Growth
|The Journal of Cell Biology|1997|388
Detection of urovirulence factors in<i>Escherichia coli</i>by multiplex polymerase chain reaction
|FEMS Immunology & Medical Microbiology|1995|317
Genetic Evidence Supporting the Fecal-Perineal-Urethral Hypothesis in Cystitis Caused by Escherichia Coli
|The Journal of Urology|1997|281